

Resource Summary Report

Generated by [NIF](#) on Sep 17, 2026

HT-1376

RRID:CVCL_1292

Type: Cell Line

Proper Citation

RRID:CVCL_1292

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_1292

Proper Citation: RRID:CVCL_1292

Description: Cell line HT-1376 is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Female

Disease: Bladder carcinoma

Defining Citation: [PMID:191628](#), [PMID:3518877](#), [PMID:3708594](#), [PMID:6244232](#), [PMID:7787250](#), [PMID:8873383](#), [PMID:9850064](#), [PMID:11416159](#), [PMID:20164919](#), [PMID:20215515](#), [PMID:22460905](#), [PMID:23401075](#), [PMID:24035680](#), [PMID:24367658](#), [PMID:24459064](#), [PMID:25997541](#), [PMID:26055179](#), [PMID:26589293](#), [PMID:27270441](#), [PMID:27397505](#), [PMID:29732388](#), [PMID:30894373](#), [PMID:31068700](#), [PMID:31978347](#), [PMID:35839778](#)

Comments: Population: Caucasian., Part of: UBC-40 urothelial bladder cancer cell line index., Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982)., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE)., Part of: BLA-40 bladder carcinoma cell line panel.

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: HT-1376

Synonyms: HT1376, HT 1376, HT 1376.T

Cross References: BTO:BTO_0003461, CLO:CLO_0004268, CLO:CLO_0004279, EFO:EFO_0002203, CLDB:cl1743, CLDB:cl1744, ArrayExpress:E-MTAB-38,

ArrayExpress:E-MTAB-783, ArrayExpress:E-MTAB-2770, ArrayExpress:E-MTAB-3610, ATCC:CRL-1472, ATCC:CRL-7927, BCRC:60058, BioGRID_ORCS_Cell_line:414, BioSample:SAMN01821564, BioSample:SAMN01821635, BioSample:SAMN03472820, BioSample:SAMN10988225, cancercellines:CVCL_1292, Cell_Model_Passport:SIDM00678, ChEMBL-Cells:ChEMBL3308398, ChEMBL-Cells:ChEMBL3308610, ChEMBL-Targets:ChEMBL612258, ChEMBL-Targets:ChEMBL614664, CLS:305100, Cosmic:715761, Cosmic:760481, Cosmic:845562, Cosmic:907066, Cosmic:925821, Cosmic:928815, Cosmic:943733, Cosmic:1046691, Cosmic:1285118, Cosmic:1285987, Cosmic:1927303, Cosmic:2050444, Cosmic:2057449, Cosmic:2444252, Cosmic:2686096, Cosmic-CLP:907066, DepMap:ACH-000724, DSMZ:ACC-397, DSMZCellDive:ACC-397, ECACC:87032402, EGA:EGAS00001000978, ENCODE:ENCBS266UUE, ENCODE:ENCBS956LPK, GDSC:907066, GEO:GSM136230, GEO:GSM142305, GEO:GSM142310, GEO:GSM827432, GEO:GSM887139, GEO:GSM888210, GEO:GSM1374560, GEO:GSM1574553, GEO:GSM1669911, IARC_TP53:3720, IGRhCellID:HT1376, IZSLER:BS TCL 70, KCLB:21472, LiGeA:CCLE_036, LINCS_LDP:LCL-1712, PharmacDB:HT1376_628_2019, PRIDE:PXD030304, Progenetix:CVCL_1292, PubChem_Cell_line:CVCL_1292, Wikidata:Q54896503

ID: CVCL_1292

Record Creation Time: 20220427T220617+0000

Record Last Update: 20260913T004530+0000

Ratings and Alerts

No rating or validation information has been found for HT-1376.

Warning: Discontinued: ATCC; CRL-7927

Population: Caucasian., Part of: UBC-40 urothelial bladder cancer cell line index., Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982)., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE)., Part of: BLA-40 bladder carcinoma cell line panel.

Data and Source Information

Source: [Cellosaurus](#)

Usage and Citation Metrics

We found 12 mentions in open access literature.

Listed below are recent publications. The full list is available at [NIF](#) .

Pece A, et al. (2026) Glycosylated LGALS3BP is highly secreted by bladder cancer cells and represents a novel urinary disease biomarker. Molecular oncology, 20(3), 823.

Stuckey JI, et al. (2026) Covalent PPAR γ inverse agonism by FX-909 reveals mechanistic insights into therapeutic targeting of PPAR γ /RXR γ -activated urothelial carcinoma. *Cell chemical biology*, 33(6), 837.

Guo X, et al. (2026) The WEE1 inhibitor azenosertib broadly enhances efficacy of antibody-drug conjugates with topoisomerase I and microtubule inhibitor payloads. *iScience*, 29(7), 116390.

Gupta KB, et al. (2024) Curcumin-Dichloroacetate Hybrid Molecule as an Antitumor Oral Drug against Multidrug-Resistant Advanced Bladder Cancers. *Cancers*, 16(17).

Dressler FF, et al. (2024) Proteomic analysis of the urothelial cancer landscape. *Nature communications*, 15(1), 4513.

Pan YC, et al. (2024) Glutathione S-transferase omega class 1 (GSTO1)-associated large extracellular vesicles are involved in tumor-associated macrophage-mediated cisplatin resistance in bladder cancer. *Molecular oncology*, 18(8), 1866.

Zhang H, et al. (2024) Role of Forkhead Box P3 in IFN γ -Mediated PD-L1 Expression and Bladder Cancer Epithelial-to-Mesenchymal Transition. *Cancer research communications*, 4(8), 2228.

Klümper N, et al. (2023) Membranous NECTIN-4 Expression Frequently Decreases during Metastatic Spread of Urothelial Carcinoma and Is Associated with Enfortumab Vedotin Resistance. *Clinical cancer research : an official journal of the American Association for Cancer Research*, 29(8), 1496.

Wang Z, et al. (2023) Comprehensive identification of onco-exaptation events in bladder cancer cell lines revealed L1PA2-SYT1 as a prognosis-relevant event. *iScience*, 26(12), 108482.

Rehman H, et al. (2022) ARID1A-deficient bladder cancer is dependent on PI3K signaling and sensitive to EZH2 and PI3K inhibitors. *JCI insight*, 7(16).

Schulz GB, et al. (2021) Therapeutic and prognostic implications of NOTCH and MAPK signaling in bladder cancer. *Cancer science*, 112(5), 1987.

Koirala S, et al. (2020) Tissue-Specific Regulation of the Wnt/ β -Catenin Pathway by PAGE4 Inhibition of Tankyrase. *Cell reports*, 32(3), 107922.